TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study
Brief Summary: Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. Current treatment with angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) is not entirely effective. Aliskiren, a direct renin inhibitor, acts on the rate limiting step of the renin-angiotensin axis. In addition to lowering the blood pressure, recent study in diabetic nephropathy suggests an independent anti-proteinuric effect. The investigators plan to conduct a randomized placebo-control cross-over study to evaluate the safety and efficacy of aliskiren in the treatment of IgA nephropathy. The investigators plan to recruit 57 patients with biopsy-proven IgA nephropathy and persistent proteinuria despite conventional therapy. They will be randomized to aliskiren for 16 weeks or no treatment, followed by cross over to the other arm after a washout period. Proteinuria, albuminuria, renal function, serum and urinary markers will be quantified. This study will explore the potential anti-proteinuric effect of aliskiren in the treatment of IgA nephropathy, which has no specific treatment at present.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Placebo | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren, Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): I, II
B: Arm Label: sparsentan; Type: EXPERIMENTAL; Interventions: Drug: sparsentan | Arm Label: irbesartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: irbesartan | Arm Label: dapagliflozin + sparsentan (Sub study); Type: EXPERIMENTAL; Interventions: Drug: sparsentan, Drug: Dapagliflozin | Arm Label: sparsentan (Sub Study); Type: EXPERIMENTAL; Interventions: Drug: sparsentan | Intervention Type: DRUG; Name: sparsentan; Assigned to Arm(s): dapagliflozin + sparsentan (Sub study), sparsentan, sparsentan (Sub Study) | Intervention Type: DRUG; Name: irbesartan; Assigned to Arm(s): irbesartan | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): dapagliflozin + sparsentan (Sub study)
C: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive therapy with: ACE-inhibitor / ARB / Statin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive and immunosuppressive therapy | Intervention Type: DRUG; Name: supportive therapy with: ACE-inhibitor / ARB / Statin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: supportive and immunosuppressive therapy; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-based Intervention to Enhance Signing of Organ Donor Cards
Brief Summary: The purpose of this study is to determine the effect of a 5-minute video intervention regarding organ donation and transplantation on increasing the number of organ donor cards signed in Northeastern Ohio Bureau of Motor Vehicles (OBMV) branches and on willingness to donate organs while living. The investigators hypothesize that persons in the intervention group will sign more donor cards and be more willing to donate organs while living than persons in the control group.


Options:
A: Arm Label: Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Arm Label: Enhanced Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Lifestyles Education | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyles Education; Assigned to Arm(s): Enhanced Standard Care
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Participant Video and Provider Cueing; Type: EXPERIMENTAL; Interventions: Behavioral: Participant Video and Provider Cueing | Intervention Type: BEHAVIORAL; Name: Participant Video and Provider Cueing; Assigned to Arm(s): Participant Video and Provider Cueing
C: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: video | Intervention Type: BEHAVIORAL; Name: video; Assigned to Arm(s): 1
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TALKS; Type: OTHER; Interventions: Behavioral: TALKS Social Worker Intervention | Arm Label: TALKS PLUS; Type: OTHER; Interventions: Behavioral: TALKS Social Worker Intervention, Other: Financial Assistance Intervention | Intervention Type: BEHAVIORAL; Name: TALKS Social Worker Intervention; Assigned to Arm(s): TALKS, TALKS PLUS | Intervention Type: OTHER; Name: Financial Assistance Intervention; Assigned to Arm(s): TALKS PLUS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Double-blinded, Placebo-controlled Study of N-acetylcysteine Plus Deferoxamine for Patients With Hypotension as Prophylaxis for Acute Renal Failure
Brief Summary: Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.


Options:
A: Arm Label: N-acetylcysteine plus deferoxamine; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine and deferoxamine | Intervention Type: DRUG; Name: N-acetylcysteine and deferoxamine; Assigned to Arm(s): N-acetylcysteine plus deferoxamine
B: Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Sodium Bicarbonate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: N-Acetylcysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-acetylcysteine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: 5% dextrose solution | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): N-Acetylcysteine | Intervention Type: OTHER; Name: 5% dextrose solution; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anodal & Cathodal tDCS for Treatment of Resistant Auditory Hallucinations in Schizophrenia
Brief Summary: The purpose of this study is to determine whether trans Direct Current Stimulation (tDCS) is effective in the treatment of auditory hallucinations in schizophrenia.


Options:
A: Arm Label: Real TMS; Type: ACTIVE_COMPARATOR; Interventions: Device: DEEP TMS H1 coil | Arm Label: Sham & real TMS; Type: PLACEBO_COMPARATOR; Interventions: Device: Deep H1 coil TMS | Intervention Type: DEVICE; Name: DEEP TMS H1 coil; Assigned to Arm(s): Real TMS | Intervention Type: DEVICE; Name: Deep H1 coil TMS; Assigned to Arm(s): Sham & real TMS
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Repetitive transcranial magnetic stimulation | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: Sham repetitive transcranial magnetic stimulation | Intervention Type: OTHER; Name: Repetitive transcranial magnetic stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Sham repetitive transcranial magnetic stimulation; Assigned to Arm(s): 2
C: Arm Label: active tDCS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: active tDCS | Arm Label: sham tDCS; Type: PLACEBO_COMPARATOR; Interventions: Procedure: sham tDCS | Intervention Type: PROCEDURE; Name: active tDCS; Assigned to Arm(s): active tDCS | Intervention Type: PROCEDURE; Name: sham tDCS; Assigned to Arm(s): sham tDCS
D: Arm Label: rTMS; Type: SHAM_COMPARATOR; Interventions: Procedure: rTMS, "repetitive transcranial magnetic stimulation", Other: rTMS | Intervention Type: PROCEDURE; Name: rTMS, "repetitive transcranial magnetic stimulation"; Assigned to Arm(s): rTMS | Intervention Type: OTHER; Name: rTMS; Assigned to Arm(s): rTMS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety of GSK Biologicals' dTpa-IPV Vaccine (Boostrix Polio) as a Booster Dose in 5 to 6-year-old Children.
Brief Summary: This phase 3b study will compare the immunogenicity and reactogenicity of the dTpa-IPV vaccine to that of a DTPa-IPV vaccine when administered as a booster dose in healthy children 5-6 years of age who have received three primary vaccination doses of DTPa-based vaccine according to the "3-5-11" month schedule recommended in Italy.

In this study, MMRV vaccine will also be co-administered to all children.


Options:
A: Intervention Type: BIOLOGICAL; Name: M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®; Assigned to Arm(s): N/A
B: Arm Label: HAV Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix® | Arm Label: HAV+MMR+V Group; Type: EXPERIMENTAL; Interventions: Biological: Havrix®, Biological: M-M-R®II, Biological: VARIVAX® | Arm Label: MMR+V→HAV Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix®, Biological: M-M-R®II, Biological: VARIVAX® | Intervention Type: BIOLOGICAL; Name: Havrix®; Assigned to Arm(s): HAV Group, HAV+MMR+V Group, MMR+V→HAV Group | Intervention Type: BIOLOGICAL; Name: M-M-R®II; Assigned to Arm(s): HAV+MMR+V Group, MMR+V→HAV Group | Intervention Type: BIOLOGICAL; Name: VARIVAX®; Assigned to Arm(s): HAV+MMR+V Group, MMR+V→HAV Group
C: Arm Label: Kinrix + M-M-R II + Varivax; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals'Kinrix®, Biological: Merck and Company's MMRII, Biological: Merck and Company's Varivax | Arm Label: Kinrix + M-M-R II -> Varivax; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals'Kinrix®, Biological: Merck and Company's MMRII, Biological: Merck and Company's Varivax | Intervention Type: BIOLOGICAL; Name: GSK Biologicals'Kinrix®; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax | Intervention Type: BIOLOGICAL; Name: Merck and Company's MMRII; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax | Intervention Type: BIOLOGICAL; Name: Merck and Company's Varivax; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax
D: Arm Label: BOOSTRIX POLIO GROUP; Type: EXPERIMENTAL; Interventions: Biological: Boostrix Polio™ 711866, Biological: Priorix Tetra TM 208136 | Arm Label: TETRAVAC GROUP; Type: ACTIVE_COMPARATOR; Interventions: Biological: Priorix Tetra TM 208136, Biological: Tetravac TM | Intervention Type: BIOLOGICAL; Name: Boostrix Polio™ 711866; Assigned to Arm(s): BOOSTRIX POLIO GROUP | Intervention Type: BIOLOGICAL; Name: Priorix Tetra TM 208136; Assigned to Arm(s): BOOSTRIX POLIO GROUP, TETRAVAC GROUP | Intervention Type: BIOLOGICAL; Name: Tetravac TM; Assigned to Arm(s): TETRAVAC GROUP

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy and Safety of Fosfomycin Plus Imipenem for the Treatment of Methicillin-resistant Staphylococcus Aureus (MRSA) Infective Endocarditis.
Brief Summary: The study evaluates the efficacy and safety of fosfomycin and imipenem for the treatment of methicillin-resistant staphyloccocus aureus infective endocarditis in comparison to vancomycin, the standard therapy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fosfomycin and imipenem | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: DRUG; Name: Fosfomycin and imipenem; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): 2
B: Arm Label: TAVI cohort; Type: N/A; Interventions: Procedure: Aortic valve replacement | Arm Label: SAVR cohort; Type: N/A; Interventions: Procedure: Aortic valve replacement | Intervention Type: PROCEDURE; Name: Aortic valve replacement; Assigned to Arm(s): SAVR cohort, TAVI cohort
C: Intervention Type: DRUG; Name: daptomycin; Assigned to Arm(s): N/A
D: Arm Label: Guideline treatment with parenteral antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guideline treatment with parenteral antibiotics | Arm Label: Oral treatment with antibiotics; Type: EXPERIMENTAL; Interventions: Drug: Oral treatment with antibiotics for endocarditis | Intervention Type: DRUG; Name: Oral treatment with antibiotics for endocarditis; Assigned to Arm(s): Oral treatment with antibiotics | Intervention Type: DRUG; Name: Guideline treatment with parenteral antibiotics; Assigned to Arm(s): Guideline treatment with parenteral antibiotics

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of Kinrix® Co-administered With Varivax®
Brief Summary: The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® \[varicella virus vaccine live\], Merck and Company) and (measles mumps rubella) MMR vaccines, compared to Kinrix co-administered with MMR vaccine alone. Both Kinrix and the second dose of Varivax are indicated in children 4-6 years of age, and there is great potential for the vaccines to be given concurrently. The aim of this trial is to demonstrate that co-administered Varivax does not negatively affect the immunogenicity or reactogenicity of Kinrix.


Options:
A: Arm Label: Kinrix + M-M-R II + Varivax; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals'Kinrix®, Biological: Merck and Company's MMRII, Biological: Merck and Company's Varivax | Arm Label: Kinrix + M-M-R II -> Varivax; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals'Kinrix®, Biological: Merck and Company's MMRII, Biological: Merck and Company's Varivax | Intervention Type: BIOLOGICAL; Name: GSK Biologicals'Kinrix®; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax | Intervention Type: BIOLOGICAL; Name: Merck and Company's MMRII; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax | Intervention Type: BIOLOGICAL; Name: Merck and Company's Varivax; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens | Intervention Type: BIOLOGICAL; Name: Inactivated types 1, 2, and 3 poliovirus, D antigens; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Inactivated types 1, 2, and 3 poliovirus, D antigens; Assigned to Arm(s): Group B
C: Arm Label: POLIORIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: PoliorixTM | Intervention Type: BIOLOGICAL; Name: PoliorixTM; Assigned to Arm(s): POLIORIX GROUP
D: Arm Label: IPV Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix | Intervention Type: BIOLOGICAL; Name: Poliorix; Assigned to Arm(s): IPV Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interdisciplinary Comprehensive Arm Rehab Evaluation (ICARE) Stroke Initiative
Brief Summary: This study is about arm and hand recovery after a stroke. The investigators are testing an experimental arm therapy called Accelerated Skill Acquisition Program (ASAP) which combines challenging, intensive and meaningful practice of tasks of the participant's choice compared to two standard types of therapy (usual and customary arm therapy totaling 30 hours and usual and customary arm therapy for a duration indicated on the therapy prescription). A second objective is to characterize current outpatient arm therapy (dosage \& content) following stroke for individuals who are eligible for ICARE. Eligible candidates must have had a stroke affecting an arm within the last 106 days.


Options:
A: Arm Label: Intensive group; Type: EXPERIMENTAL; Interventions: Procedure: Cognitive rehabilitation | Arm Label: Conventional group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cognitive rehabilitation | Intervention Type: PROCEDURE; Name: Cognitive rehabilitation; Assigned to Arm(s): Conventional group, Intensive group
B: Arm Label: Higher-intensity RT group; Type: EXPERIMENTAL; Interventions: Device: RT, Behavioral: Conventional rehabilitation (CR) | Arm Label: Lower-intensity RT group; Type: EXPERIMENTAL; Interventions: Device: RT, Behavioral: Conventional rehabilitation (CR) | Arm Label: Conventional rehabilitation (CR) group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional rehabilitation (CR) | Intervention Type: DEVICE; Name: RT; Assigned to Arm(s): Higher-intensity RT group, Lower-intensity RT group | Intervention Type: BEHAVIORAL; Name: Conventional rehabilitation (CR); Assigned to Arm(s): Conventional rehabilitation (CR) group, Higher-intensity RT group, Lower-intensity RT group
C: Arm Label: group 1: standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: standard physiotherapy | Arm Label: group 2: experimental physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: experimental physiotherapy | Intervention Type: PROCEDURE; Name: standard physiotherapy; Assigned to Arm(s): group 1: standard physiotherapy | Intervention Type: PROCEDURE; Name: experimental physiotherapy; Assigned to Arm(s): group 2: experimental physiotherapy
D: Arm Label: ASAP; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: DEUCC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dose-Equivalent Usual & Customary Care - DEUCC | Arm Label: UCC; Type: OTHER; Interventions: Behavioral: Usual and Customary Care - UCC | Intervention Type: BEHAVIORAL; Name: Accelerated Skill Acquisition Program (ASAP); Assigned to Arm(s): ASAP | Intervention Type: BEHAVIORAL; Name: Dose-Equivalent Usual & Customary Care - DEUCC; Assigned to Arm(s): DEUCC | Intervention Type: BEHAVIORAL; Name: Usual and Customary Care - UCC; Assigned to Arm(s): UCC

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interdisciplinary Comprehensive Arm Rehab Evaluation (ICARE) Stroke Initiative
Brief Summary: This study is about arm and hand recovery after a stroke. The investigators are testing an experimental arm therapy called Accelerated Skill Acquisition Program (ASAP) which combines challenging, intensive and meaningful practice of tasks of the participant's choice compared to two standard types of therapy (usual and customary arm therapy totaling 30 hours and usual and customary arm therapy for a duration indicated on the therapy prescription). A second objective is to characterize current outpatient arm therapy (dosage \& content) following stroke for individuals who are eligible for ICARE. Eligible candidates must have had a stroke affecting an arm within the last 106 days.


Options:
A: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Instruction in physical training program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Instruction in physical training program; Assigned to Arm(s): Intervention arm
B: Arm Label: physical fitness training; Type: EXPERIMENTAL; Interventions: Procedure: physical fitness training | Arm Label: relaxation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: relaxation | Intervention Type: PROCEDURE; Name: physical fitness training; Assigned to Arm(s): physical fitness training | Intervention Type: PROCEDURE; Name: relaxation; Assigned to Arm(s): relaxation
C: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: FAST protocol; Type: EXPERIMENTAL; Interventions: Behavioral: FAST protocol | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: FAST protocol; Assigned to Arm(s): FAST protocol
D: Arm Label: ASAP; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: DEUCC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dose-Equivalent Usual & Customary Care - DEUCC | Arm Label: UCC; Type: OTHER; Interventions: Behavioral: Usual and Customary Care - UCC | Intervention Type: BEHAVIORAL; Name: Accelerated Skill Acquisition Program (ASAP); Assigned to Arm(s): ASAP | Intervention Type: BEHAVIORAL; Name: Dose-Equivalent Usual & Customary Care - DEUCC; Assigned to Arm(s): DEUCC | Intervention Type: BEHAVIORAL; Name: Usual and Customary Care - UCC; Assigned to Arm(s): UCC

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Study of Different Pain Scores in Single Transumbilical Incision Laparoscopic Cholecystectomy Versus Classic Laparoscopic Cholecystectomy
Brief Summary: The attempt to further reduce the operative trauma in laparoscopic cholecystectomy led in new techniques, as Natural Orifice Transluminal Endoscopic Surgery (NOTES) and Single Incision Laparoscopic Surgery (SILS). These new techniques are considered as painless procedures, but there are not any publications to study a possible different pain score in new techniques versus classic laparoscopic cholecystectomy. In this randomized controlled study the researchers have investigated the pain scores, the incidence of nausea and vomiting and analgesics request after the procedure.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Laparoscopic cholecystectomy surgery | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Laparoscopic cholecystectomy surgery | Intervention Type: DEVICE; Name: Laparoscopic cholecystectomy surgery; Assigned to Arm(s): 1, 2
B: Arm Label: LESS cholecystectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cholecystectomy | Arm Label: Standard LAP-CHOLE; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cholecystectomy | Arm Label: LESS Cholecystectomy not blind; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cholecystectomy | Intervention Type: PROCEDURE; Name: Cholecystectomy; Assigned to Arm(s): LESS Cholecystectomy not blind, LESS cholecystectomy, Standard LAP-CHOLE
C: Arm Label: Laparoscopic Cholecystectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Cholecystectomy | Arm Label: SILS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: SILS | Intervention Type: PROCEDURE; Name: Laparoscopic Cholecystectomy; Assigned to Arm(s): Laparoscopic Cholecystectomy | Intervention Type: PROCEDURE; Name: SILS; Assigned to Arm(s): SILS
D: Arm Label: Multi port; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 4-Ports Cholecystectomy (4PC) | Arm Label: Single port; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single-Port Cholecystectomy (SPC) | Intervention Type: PROCEDURE; Name: 4-Ports Cholecystectomy (4PC); Assigned to Arm(s): Multi port | Intervention Type: PROCEDURE; Name: Single-Port Cholecystectomy (SPC); Assigned to Arm(s): Single port

Answer: C